The Experts below are selected from a list of 29040 Experts worldwide ranked by ideXlab platform
Jost B Jonas - One of the best experts on this subject based on the ideXlab platform.
-
Intraocular availability of triamcinolone acetonide after Intravitreal Injection.
American journal of ophthalmology, 2004Co-Authors: Jost B JonasAbstract:Abstract Background To evaluate the intraocular concentration of triamcinolone acetonide after Intravitreal Injection. Methods The prospective clinical interventional case series study included 17 patients who had received a 20 to 25-mg Intravitreal Injection of triamcinolone acetonide as treatment for exudative age-related macular degeneration, diffuse diabetic macular edema, or retinal vein occlusions. During a secondary intraocular surgery taking place 4.1 weeks to 25.7 months after the Intravitreal Injection, aqueous humor samples were obtained. None of the eyes were vitrectomized. Results In the aqueous humor samples, triamcinolone acetonide was in low, but measurable, concentrations detected up to 1.5 years after the Intravitreal Injection. Concentrations found in samples obtained during the first 6 months, or 7 to 12 months, respectively, after the Injection ranged between 3.0 μg/l and 436 μg/l, and between 0.0 μg/l and 11.2 μg/l, respectively. Conclusions After Injection of triamcinolone acetonide, triamcinolone can be present in measurable concentrations up to 1.5 years after the application.
-
Intravitreal Injection of triamcinolone for diffuse diabetic macular edema.
Archives of ophthalmology (Chicago Ill. : 1960), 2003Co-Authors: Jost B Jonas, Ingrid Kreissig, Antje Söfker, Robert F. DegenringAbstract:Objective To evaluate the clinical outcome of an Intravitreal Injection of triamcinolone acetonide as treatment of diffuse diabetic macular edema. Participants This prospective, interventional, clinical case series study included 20 patients (26 eyes) who received an Intravitreal Injection of 25 mg of triamcinolone acetonide for treatment of diffuse diabetic macular edema. Mean ± SD follow-up time was 6.64 ± 6.10 months. The study group was compared with a control group of 16 patients who underwent macular grid laser coagulation. Main Outcome Measures Visual acuity and intraocular pressure. Results In the study group, visual acuity improved significantly (P Conclusion Intravitreal Injection of 25 mg of triamcinolone acetonide may be beneficial for improving visual acuity in patients with clinically significant diffuse diabetic macular edema.
-
regression of neovascular iris vessels by Intravitreal Injection of crystalline cortisone
Journal of Glaucoma, 2001Co-Authors: Jost B Jonas, Jochen K Hayler, Antje Söfker, Songhomitra PandajonasAbstract:PURPOSE: To report the clinical outcome of patients who received an Intravitreal Injection of crystalline triamcinolone acetonide as treatment of neovascular glaucoma. PATIENTS AND METHODS: The study included 14 eyes of 14 patients with secondary neovascular glaucoma attributable to proliferative diabetic retinopathy (n = 9) or ischemic central retinal vein occlusion (n = 5). All patients received an Intravitreal Injection of 20 mg of crystalline triamcinolone acetonide as the only procedure (n = 4) or in combination with additional procedures, such as goniosynechiolysis (n = 1), phacoemulsification and intraocular lens implantation (n = 2), or transscleral peripheral retinal cryocoagulation (n = 7). Mean follow-up time was 3.10 +/- 2.40 months (median, 3.5 months; range, 0.50-5.7 months). A goniosynechiolysis was carried out in those patients in whom the anterior chamber was circumferentially closed. RESULTS: After surgery, including the first days after surgery, the patients were nearly pain-free. Intraocular pressure was significantly (P < 0.01) reduced from 33.4 +/- 14.5 mm Hg before surgery to 20.7 +/- 8.2 mm Hg at the end of the follow-up period. Postoperative visual acuity (mean, 0.09 +/- 0.07; median, 0.10; range, finger counting to 0.25) was slightly but not significantly (P = 0.31) better than the preoperative values. Degree of rubeosis iridis decreased significantly (P = 0.02) from 2.6 +/- 1.3 relative units to 1.3 +/- 1.2 relative units. When considering only the four patients for whom the intraocular cortisone Injection was the only procedure performed, mean intraocular pressure decreased from 26.5 +/- 12.1 mm Hg to 21.75 +/- 11.3 mm Hg. CONCLUSIONS: Intravitreal Injection of crystalline cortisone with most of the vehicle removed may be a potentially useful additional tool in the treatment of neovascular glaucoma.
-
Intravitreal Injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy
American Journal of Ophthalmology, 2001Co-Authors: Jost B Jonas, Jochen K Hayler, Antje Söfker, Songhomitra PandajonasAbstract:Abstract PURPOSE: To report the clinical outcome and complications of Intravitreal Injections of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative diabetic retinopathy. METHODS: The prospective, interventional case series study included 29 consecutive patients (29 eyes) who underwent pars plana vitrectomy for treatment of complicated proliferative diabetic retinopathy associated with central retinal traction detachment. All patients received an Intravitreal Injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery, and were operated on by the same surgeon. Mean follow-up time was 1.4 ± 1.1 months (median, 1 month; range, 0.30 to 4.9 months). RESULTS: At the end of the follow-up period, the retina was attached in 26 of the 29 patients (89.7%). In three of the 29 patients (10.3%), a retinal redetachment had occurred. None of the patients developed iris neovascularization, and the iris neovascularization, present preoperatively in 12 patients, slightly to markedly regressed in all 12 patients. Preoperative and postoperative intraocular pressure values ( P = .72) and blood glucose measurements did not vary significantly. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient and resolved spontaneously within 4 days. CONCLUSIONS: The present clinical study suggests that Intravitreal Injection of crystalline cortisone with most of the vehicle removed seems to be well tolerated by eyes undergoing pars plana vitrectomy for treatment of complicated diabetic proliferative retinopathy. In view of the antiphlogistic and antiproliferative effect of cortisone, future randomized clinical trials may be indicated to investigate further the role of Intravitreal Injection of crystalline cortisone in the treatment of proliferative diabetic retinopathy.
-
Intravitreal Injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy
British Journal of Ophthalmology, 2000Co-Authors: Jost B Jonas, Jochen K Hayler, Songhomitra PandajonasAbstract:AIM To report on clinical outcome and complications of Intravitreal Injection of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative vitreoretinopathy. METHODS The study included all 16 patients who underwent pars plana vitrectomy for treatment of proliferative vitreoretinopathy, who received an Intravitreal Injection of 10–20 mg crystalline triamcinolone acetonide at the end of surgery, and who were operated on by the same surgeon. Most of the vehicle of the solution containing the cortisone crystals was removed before performing the Injection. Mean follow up time was 1.64 (SD 2.15) months (median 1.23 months; range 0.20–9.20 months). The study group was compared with a control group which consisted of 144 patients undergoing pars plana vitrectomy for proliferative vitreoretinopathy performed by the same surgeon. RESULTS In the study group compared with the control group, intraocular inflammation, as estimated clinically by slit lamp biomicroscopy, was lower, appearance of the fundus upon ophthalmoscopy in the first postoperative week was clearer, and postoperative pain in the first two postoperative days was reduced. Intraocular pressure measured at the end of the first postoperative week did not vary significantly between the groups. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient. Postoperative infectious endophthalmitis was not encountered. CONCLUSIONS This pilot study suggests that Intravitreal Injection of crystalline cortisone with most of the vehicle removed is not toxic to intraocular structures, reduces postoperative intraocular inflammation, and may be a potentially useful additional tool in the treatment of proliferative vitreoretinopathy.
Songhomitra Pandajonas - One of the best experts on this subject based on the ideXlab platform.
-
regression of neovascular iris vessels by Intravitreal Injection of crystalline cortisone
Journal of Glaucoma, 2001Co-Authors: Jost B Jonas, Jochen K Hayler, Antje Söfker, Songhomitra PandajonasAbstract:PURPOSE: To report the clinical outcome of patients who received an Intravitreal Injection of crystalline triamcinolone acetonide as treatment of neovascular glaucoma. PATIENTS AND METHODS: The study included 14 eyes of 14 patients with secondary neovascular glaucoma attributable to proliferative diabetic retinopathy (n = 9) or ischemic central retinal vein occlusion (n = 5). All patients received an Intravitreal Injection of 20 mg of crystalline triamcinolone acetonide as the only procedure (n = 4) or in combination with additional procedures, such as goniosynechiolysis (n = 1), phacoemulsification and intraocular lens implantation (n = 2), or transscleral peripheral retinal cryocoagulation (n = 7). Mean follow-up time was 3.10 +/- 2.40 months (median, 3.5 months; range, 0.50-5.7 months). A goniosynechiolysis was carried out in those patients in whom the anterior chamber was circumferentially closed. RESULTS: After surgery, including the first days after surgery, the patients were nearly pain-free. Intraocular pressure was significantly (P < 0.01) reduced from 33.4 +/- 14.5 mm Hg before surgery to 20.7 +/- 8.2 mm Hg at the end of the follow-up period. Postoperative visual acuity (mean, 0.09 +/- 0.07; median, 0.10; range, finger counting to 0.25) was slightly but not significantly (P = 0.31) better than the preoperative values. Degree of rubeosis iridis decreased significantly (P = 0.02) from 2.6 +/- 1.3 relative units to 1.3 +/- 1.2 relative units. When considering only the four patients for whom the intraocular cortisone Injection was the only procedure performed, mean intraocular pressure decreased from 26.5 +/- 12.1 mm Hg to 21.75 +/- 11.3 mm Hg. CONCLUSIONS: Intravitreal Injection of crystalline cortisone with most of the vehicle removed may be a potentially useful additional tool in the treatment of neovascular glaucoma.
-
Intravitreal Injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy
American Journal of Ophthalmology, 2001Co-Authors: Jost B Jonas, Jochen K Hayler, Antje Söfker, Songhomitra PandajonasAbstract:Abstract PURPOSE: To report the clinical outcome and complications of Intravitreal Injections of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative diabetic retinopathy. METHODS: The prospective, interventional case series study included 29 consecutive patients (29 eyes) who underwent pars plana vitrectomy for treatment of complicated proliferative diabetic retinopathy associated with central retinal traction detachment. All patients received an Intravitreal Injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery, and were operated on by the same surgeon. Mean follow-up time was 1.4 ± 1.1 months (median, 1 month; range, 0.30 to 4.9 months). RESULTS: At the end of the follow-up period, the retina was attached in 26 of the 29 patients (89.7%). In three of the 29 patients (10.3%), a retinal redetachment had occurred. None of the patients developed iris neovascularization, and the iris neovascularization, present preoperatively in 12 patients, slightly to markedly regressed in all 12 patients. Preoperative and postoperative intraocular pressure values ( P = .72) and blood glucose measurements did not vary significantly. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient and resolved spontaneously within 4 days. CONCLUSIONS: The present clinical study suggests that Intravitreal Injection of crystalline cortisone with most of the vehicle removed seems to be well tolerated by eyes undergoing pars plana vitrectomy for treatment of complicated diabetic proliferative retinopathy. In view of the antiphlogistic and antiproliferative effect of cortisone, future randomized clinical trials may be indicated to investigate further the role of Intravitreal Injection of crystalline cortisone in the treatment of proliferative diabetic retinopathy.
-
Intravitreal Injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy
British Journal of Ophthalmology, 2000Co-Authors: Jost B Jonas, Jochen K Hayler, Songhomitra PandajonasAbstract:AIM To report on clinical outcome and complications of Intravitreal Injection of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative vitreoretinopathy. METHODS The study included all 16 patients who underwent pars plana vitrectomy for treatment of proliferative vitreoretinopathy, who received an Intravitreal Injection of 10–20 mg crystalline triamcinolone acetonide at the end of surgery, and who were operated on by the same surgeon. Most of the vehicle of the solution containing the cortisone crystals was removed before performing the Injection. Mean follow up time was 1.64 (SD 2.15) months (median 1.23 months; range 0.20–9.20 months). The study group was compared with a control group which consisted of 144 patients undergoing pars plana vitrectomy for proliferative vitreoretinopathy performed by the same surgeon. RESULTS In the study group compared with the control group, intraocular inflammation, as estimated clinically by slit lamp biomicroscopy, was lower, appearance of the fundus upon ophthalmoscopy in the first postoperative week was clearer, and postoperative pain in the first two postoperative days was reduced. Intraocular pressure measured at the end of the first postoperative week did not vary significantly between the groups. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient. Postoperative infectious endophthalmitis was not encountered. CONCLUSIONS This pilot study suggests that Intravitreal Injection of crystalline cortisone with most of the vehicle removed is not toxic to intraocular structures, reduces postoperative intraocular inflammation, and may be a potentially useful additional tool in the treatment of proliferative vitreoretinopathy.
Yasuo Tano - One of the best experts on this subject based on the ideXlab platform.
-
Complications in patients after Intravitreal Injection of bevacizumab.
Acta ophthalmologica, 2007Co-Authors: Chiharu Shima, Hirokazu Sakaguchi, Fumi Gomi, Motohiro Kamei, Yasushi Ikuno, Yusuke Oshima, Miki Sawa, Motokazu Tsujikawa, Shunji Kusaka, Yasuo TanoAbstract:. Purpose: To report complications in patients after Intravitreal Injection of bevacizumab to treat ocular diseases associated with vascular endothelial growth factor. Methods: We retrospectively reviewed the systemic and ocular complications that developed within 2 months of each Intravitreal Injection of bevacizumab in 707 patients (1300 Injections) with intraocular neovascularization or macular oedema. Results: Nine ocular (1.27%) and eight systemic (1.13%) complications occurred in 707 patients. The ocular complications included corneal abrasion (n = 2), chemosis (n = 2), lens injury (n = 1), ocular inflammation (n = 2), retinal pigment epithelial tear (n = 1) and acute vision loss (n = 1). The systemic complications included cerebral infarction (n = 1), elevation of systolic blood pressure (n = 2), facial skin redness (n = 1), itchy diffuse rash (n = 1) and menstrual irregularities (n = 3). Conclusion: Intravitreal Injection of bevacizumab may cause systemic or ocular complications. Caution is advised when considering Intravitreal Injection of this drug.
-
Intravitreal Injection of bevacizumab for choroidal neovascularisation associated with pathological myopia
British Journal of Ophthalmology, 2007Co-Authors: Hirokazu Sakaguchi, Fumi Gomi, Motohiro Kamei, Yasushi Ikuno, Yusuke Oshima, Miki Sawa, Motokazu Tsujikawa, Shunji Kusaka, Yasuo TanoAbstract:Aim: To assess the efficacy and safety of an Intravitreal Injection of bevacizumab (Avastin®) for myopic choroidal neovascularisation (mCNV). Methods: Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months. Results: The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed. Conclusion: Intravitreal Injection of bevacizumab seems to be an effective and safe treatment for mCNV.
-
regression of iris neovascularization after Intravitreal Injection of bevacizumab in patients with proliferative diabetic retinopathy
American Journal of Ophthalmology, 2006Co-Authors: Yusuke Oshima, Fumi Gomi, Hirokazu Sakaguchi, Yasuo TanoAbstract:Purpose To assess the short-term safety and efficacy of Intravitreal Injection of bevacizumab for iris neovascularization (INV). Design Noncomparative, interventional case series. Methods Intravitreal bevacizumab was injected in seven eyes of five patients with INV that was associated with proliferative diabetic retinopathy (PDR). The main outcome measurements were visual acuity, intraocular pressure (IOP), and regression of INV by fluorescein angiography before and one week, one month, and two months after Injection. Results Regression of INV was confirmed in all eyes (100%) from one week after Injection. Repeated Injections stabilized the recurrence (two eyes; 29%) that was observed two months after the initial Injection. The visual acuity remained stable or improved, and the intraocular pressure was controlled in six eyes (86%) throughout the follow-up period. No inflammation or complications were observed. Conclusions Intravitreal Injection of bevacizumab may be an effective and safe alternative for patients with INV that is refractory to conventional treatments.
-
Examination of purification methods and development of Intravitreal Injection of triamcinolone acetonide.
Japanese Journal of Ophthalmology, 2005Co-Authors: Masako Oishi, Shinichiro Maeda, Ayumi Nakamura, Nobuo Kurokawa, Nobuyuki Ohguro, Yasuo TanoAbstract:Purpose Intravitreal Injection of triamcinolone acetonide (TA) is used in ophthalmic treatment, but the reliability of commercially available TA preparations has still not been established. We evaluated two previously reported purification methods, and developed a more reliable TA Injection which can be prepared in a hospital pharmacy.
Jochen K Hayler - One of the best experts on this subject based on the ideXlab platform.
-
regression of neovascular iris vessels by Intravitreal Injection of crystalline cortisone
Journal of Glaucoma, 2001Co-Authors: Jost B Jonas, Jochen K Hayler, Antje Söfker, Songhomitra PandajonasAbstract:PURPOSE: To report the clinical outcome of patients who received an Intravitreal Injection of crystalline triamcinolone acetonide as treatment of neovascular glaucoma. PATIENTS AND METHODS: The study included 14 eyes of 14 patients with secondary neovascular glaucoma attributable to proliferative diabetic retinopathy (n = 9) or ischemic central retinal vein occlusion (n = 5). All patients received an Intravitreal Injection of 20 mg of crystalline triamcinolone acetonide as the only procedure (n = 4) or in combination with additional procedures, such as goniosynechiolysis (n = 1), phacoemulsification and intraocular lens implantation (n = 2), or transscleral peripheral retinal cryocoagulation (n = 7). Mean follow-up time was 3.10 +/- 2.40 months (median, 3.5 months; range, 0.50-5.7 months). A goniosynechiolysis was carried out in those patients in whom the anterior chamber was circumferentially closed. RESULTS: After surgery, including the first days after surgery, the patients were nearly pain-free. Intraocular pressure was significantly (P < 0.01) reduced from 33.4 +/- 14.5 mm Hg before surgery to 20.7 +/- 8.2 mm Hg at the end of the follow-up period. Postoperative visual acuity (mean, 0.09 +/- 0.07; median, 0.10; range, finger counting to 0.25) was slightly but not significantly (P = 0.31) better than the preoperative values. Degree of rubeosis iridis decreased significantly (P = 0.02) from 2.6 +/- 1.3 relative units to 1.3 +/- 1.2 relative units. When considering only the four patients for whom the intraocular cortisone Injection was the only procedure performed, mean intraocular pressure decreased from 26.5 +/- 12.1 mm Hg to 21.75 +/- 11.3 mm Hg. CONCLUSIONS: Intravitreal Injection of crystalline cortisone with most of the vehicle removed may be a potentially useful additional tool in the treatment of neovascular glaucoma.
-
Intravitreal Injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy
American Journal of Ophthalmology, 2001Co-Authors: Jost B Jonas, Jochen K Hayler, Antje Söfker, Songhomitra PandajonasAbstract:Abstract PURPOSE: To report the clinical outcome and complications of Intravitreal Injections of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative diabetic retinopathy. METHODS: The prospective, interventional case series study included 29 consecutive patients (29 eyes) who underwent pars plana vitrectomy for treatment of complicated proliferative diabetic retinopathy associated with central retinal traction detachment. All patients received an Intravitreal Injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery, and were operated on by the same surgeon. Mean follow-up time was 1.4 ± 1.1 months (median, 1 month; range, 0.30 to 4.9 months). RESULTS: At the end of the follow-up period, the retina was attached in 26 of the 29 patients (89.7%). In three of the 29 patients (10.3%), a retinal redetachment had occurred. None of the patients developed iris neovascularization, and the iris neovascularization, present preoperatively in 12 patients, slightly to markedly regressed in all 12 patients. Preoperative and postoperative intraocular pressure values ( P = .72) and blood glucose measurements did not vary significantly. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient and resolved spontaneously within 4 days. CONCLUSIONS: The present clinical study suggests that Intravitreal Injection of crystalline cortisone with most of the vehicle removed seems to be well tolerated by eyes undergoing pars plana vitrectomy for treatment of complicated diabetic proliferative retinopathy. In view of the antiphlogistic and antiproliferative effect of cortisone, future randomized clinical trials may be indicated to investigate further the role of Intravitreal Injection of crystalline cortisone in the treatment of proliferative diabetic retinopathy.
-
Intravitreal Injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy
British Journal of Ophthalmology, 2000Co-Authors: Jost B Jonas, Jochen K Hayler, Songhomitra PandajonasAbstract:AIM To report on clinical outcome and complications of Intravitreal Injection of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative vitreoretinopathy. METHODS The study included all 16 patients who underwent pars plana vitrectomy for treatment of proliferative vitreoretinopathy, who received an Intravitreal Injection of 10–20 mg crystalline triamcinolone acetonide at the end of surgery, and who were operated on by the same surgeon. Most of the vehicle of the solution containing the cortisone crystals was removed before performing the Injection. Mean follow up time was 1.64 (SD 2.15) months (median 1.23 months; range 0.20–9.20 months). The study group was compared with a control group which consisted of 144 patients undergoing pars plana vitrectomy for proliferative vitreoretinopathy performed by the same surgeon. RESULTS In the study group compared with the control group, intraocular inflammation, as estimated clinically by slit lamp biomicroscopy, was lower, appearance of the fundus upon ophthalmoscopy in the first postoperative week was clearer, and postoperative pain in the first two postoperative days was reduced. Intraocular pressure measured at the end of the first postoperative week did not vary significantly between the groups. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient. Postoperative infectious endophthalmitis was not encountered. CONCLUSIONS This pilot study suggests that Intravitreal Injection of crystalline cortisone with most of the vehicle removed is not toxic to intraocular structures, reduces postoperative intraocular inflammation, and may be a potentially useful additional tool in the treatment of proliferative vitreoretinopathy.
Carsten H. Meyer - One of the best experts on this subject based on the ideXlab platform.
-
intraocular pharmacokinetics of ranibizumab following a single Intravitreal Injection in humans
American Journal of Ophthalmology, 2012Co-Authors: Tim U Krohne, Frank G Holz, Zengping Liu, Carsten H. MeyerAbstract:Purpose To investigate intraocular concentrations and pharmacokinetics of ranibizumab after a single Intravitreal Injection in humans. Design Prospective, noncomparative, interventional case series. Methods We included 18 nonvitrectomized eyes of 18 patients (age range, 61–85 years) that were diagnosed with both clinically significant cataract and macular edema secondary to either exudative age-related macular degeneration, diabetic maculopathy, or retinal vein occlusion. Each eye received a single Intravitreal Injection of 0.5 mg ranibizumab. An aqueous humor sample was obtained during cataract surgery between 1 and 37 days after Injection. Concentrations of unbound ranibizumab in these samples were quantified by enzyme-linked immunosorbent assay. Results Ranibizumab concentration in aqueous humor peaked the first day after Injection (range, 36.9–66.1 μg/mL) and subsequently declined in a mono-exponential fashion. Nonlinear regression analysis determined an initial peak concentration (c max ) of 56.1 μg/mL and an elimination half-life (t 1/2 ) of 7.19 days with a coefficient of determination (R 2 ) of 0.90. Correction of ranibizumab concentrations for ocular volume as calculated from axial length measurements did not alter regression analysis results significantly (t 1/2 , 7.15 days; R 2 , 0.89). Conclusions In human nonvitrectomized eyes, the aqueous half-life of 0.5 mg Intravitreally injected ranibizumab is 7.19 days, slightly shorter than the half-life of 9.82 days previously determined for bevacizumab by comparable methods.
-
Choroidal detachment after an uneventful Intravitreal Injection.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2010Co-Authors: Carsten H. Meyer, Christian K. Brinkmann, H.-m. HelbAbstract:Abstract Purpose: The purpose of this report was to describe a case of choroidal detachment after an uneventful Intravitreal Injection using a 30-gauge needle. Methods: An 88-year-old patient with acute onset of neovascular age-related macular degeneration developed a choroidal detachment after an uneventful Intravitreal Injection in the infero-temporal aspect of the fundus. Results: The patient described no symptoms related to the chorioretinal detachment. Additional Intravitreal Injections were required to treat an active subfoveal choroidal neovascularization. These Injections were placed at the contralateral side in the supero-nasal quadrant. She was closely watched on a 2-week follow-up schedule. The choroidal detachment remained asymptomatic for the patient and resolved spontaneously, and the best corrected visual acuity improved from 0.2 to 0.63 during a 6-month follow-up. A mild hyperpigmentation remained at this location. Conclusion: Asymptomatic choroidal detachments may occur after Intravitreal...
-
intraocular pharmacokinetics of bevacizumab after a single Intravitreal Injection in humans
American Journal of Ophthalmology, 2008Co-Authors: Tim U Krohne, Nicole Eter, Frank G Holz, Carsten H. MeyerAbstract:Purpose To investigate intraocular concentrations and pharmacokinetics of bevacizumab after a single Intravitreal Injection in humans. Design Prospective, noncomparative, interventional case series. Methods We included 30 nonvitrectomized eyes of 30 patients (age range, 43 to 93 years) diagnosed with clinically significant cataract and concurrent macular edema secondary to neovascular age-related macular degeneration, diabetic retinopathy, or retinal venous occlusion in the same eye. All patients received an Intravitreal Injection of 1.5 mg bevacizumab. Between one and 53 days after Injection, an aqueous humor sample was obtained during elective cataract surgery. Concentrations of unbound bevacizumab in these samples were quantified by enzyme-linked immunosorbent assay. Results Concentration of bevacizumab in aqueous humor peaked on the first day after Injection with a mean concentration (c max ) of 33.3 μg/ml (range, 16.6 to 42.5 μg/ml) and subsequently declined in a monoexponential fashion. Nonlinear regression analysis determined an elimination half-time (t 1/2 ) of 9.82 days ( R 2 = 0.81). No significant differences between diagnosis subgroups were noted. Conclusions In human nonvitrectomized eyes, the aqueous half-life of 1.5 mg Intravitreally injected bevacizumab is 9.82 days.
